Shionogi & Co (($JP:4507)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Shionogi & Co.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

▎药明康德内容团队编辑盐野义（Shionogi）今日宣布，其与UBE共同开发的在研呼吸道合胞病毒（RSV）口服抗病毒疗法S-337395，在2期临床试验中达到主要终点。接受最高剂量S-337395治疗的受试者，其病毒载量下降近90%。该研究为一项随机、安慰剂对照、双盲的2期试验，在健康成人中进行。研究评估了S-337395口服疗法（每日一次 ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.